Offering finances studies, trials and technology platform development
By Devika Patel
Knoxville, Tenn., Feb. 4 - Dicerna Pharmaceuticals Inc. said the underwriters for its initial public offering of stock opted to exercise the deal's $13.5 million greenshoe in full for total proceeds of $103.5 million. The deal was announced Dec. 31 and priced for $90 million with the greenshoe on Jan. 30.
The company sold 6.9 million common shares at $15.00 apiece. Of the shares, 900,000 were part of the fully exercised greenshoe.
Jefferies LLC, Leerink Partners LLC, and Stifel, Nicolaus & Co., Inc. were the joint bookrunners.
Proceeds will be used for preclinical studies and clinical trials, technology platform development, working capital and general corporate purposes.
The biopharmaceutical company is based in Watertown, Mass. It expects its shares will trade on the Nasdaq under the symbol "DRNA."
| Issuer: | Dicerna Pharmaceuticals Inc.
|
| Issue: | Common stock
|
| Amount: | $103.5 million, including $13.5 million greenshoe
|
| Shares: | 6.9 million
|
| Price: | $15.00
|
| Warrants: | No
|
| Bookrunners: | Jefferies LLC, Leerink Partners LLC, and Stifel, Nicolaus & Co., Inc.
|
| Co-lead manager: | Robert W. Baird & Co. Inc.
|
| Announcement date: | Dec. 31
|
| Pricing date: | Jan. 30
|
| Settlement date: | Feb. 4
|
| Stock exchange: | Nasdaq: DRNA
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
